RU2009108147A - Иммуноглобулины - Google Patents
Иммуноглобулины Download PDFInfo
- Publication number
- RU2009108147A RU2009108147A RU2009108147/10A RU2009108147A RU2009108147A RU 2009108147 A RU2009108147 A RU 2009108147A RU 2009108147/10 A RU2009108147/10 A RU 2009108147/10A RU 2009108147 A RU2009108147 A RU 2009108147A RU 2009108147 A RU2009108147 A RU 2009108147A
- Authority
- RU
- Russia
- Prior art keywords
- hosm
- seq
- antibody
- interaction
- patient
- Prior art date
Links
- 108060003951 Immunoglobulin Proteins 0.000 title 1
- 102000018358 immunoglobulin Human genes 0.000 title 1
- 229940072221 immunoglobulins Drugs 0.000 title 1
- 101000992170 Homo sapiens Oncostatin-M Proteins 0.000 claims abstract 12
- 102000043703 human OSM Human genes 0.000 claims abstract 12
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims abstract 6
- 238000002965 ELISA Methods 0.000 claims abstract 4
- 101000599056 Homo sapiens Interleukin-6 receptor subunit beta Proteins 0.000 claims abstract 4
- 201000010099 disease Diseases 0.000 claims abstract 4
- 230000003993 interaction Effects 0.000 claims abstract 4
- 108090000630 Oncostatin M Proteins 0.000 claims abstract 2
- 239000000427 antigen Substances 0.000 claims abstract 2
- 102000036639 antigens Human genes 0.000 claims abstract 2
- 108091007433 antigens Proteins 0.000 claims abstract 2
- 230000002917 arthritic effect Effects 0.000 claims abstract 2
- 208000035475 disorder Diseases 0.000 claims abstract 2
- 239000012634 fragment Substances 0.000 claims abstract 2
- 238000000034 method Methods 0.000 claims abstract 2
- 239000000203 mixture Substances 0.000 claims abstract 2
- 201000008482 osteoarthritis Diseases 0.000 claims abstract 2
- 239000008194 pharmaceutical composition Substances 0.000 claims abstract 2
- 206010039073 rheumatoid arthritis Diseases 0.000 claims abstract 2
- 230000001225 therapeutic effect Effects 0.000 claims abstract 2
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
- C07K16/244—Interleukins [IL]
- C07K16/248—IL-6
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/42—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against immunoglobulins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Genetics & Genomics (AREA)
- Biochemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Biophysics (AREA)
- Neurology (AREA)
- Pulmonology (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Microbiology (AREA)
- Physical Education & Sports Medicine (AREA)
- Psychiatry (AREA)
- Urology & Nephrology (AREA)
- Vascular Medicine (AREA)
- Hospice & Palliative Care (AREA)
- Dermatology (AREA)
- Mycology (AREA)
- Epidemiology (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Abstract
1. Антитело или антигенсвязывающий фрагмент, которые конкурентно ингибируют связывание гуманизированного терапевтического антитела, специфически связывающего онкостатин М человека (hOSM) и модулирующего взаимодействие между hOSM и gp130, содержащего тяжелую цепь с SEQ ID NO: 11 и легкую цепь с SEQ ID NO: 12, с OSM, в частности hOSM, более конкретно с сайтом II hOSM, в твердофазном иммуноферментном анализе (ELISA) при условии, что это конкурирующее антитело не содержит CDRH3 с SEQ ID NO: 42. ! 2. Фармацевтическая композиция, содержащая конкурирующее антитело по п.1. ! 3. Способ лечения пациента человека, страдающего заболеванием или расстройством, чувствительным к модуляции взаимодействия между hOSM и gp130 (таким как артритное заболевание, например ревматоидный артрит и/или остеоартрит), включающий стадию введения указанному пациенту терапевтически эффективного количества композиции по п.2.
Claims (3)
1. Антитело или антигенсвязывающий фрагмент, которые конкурентно ингибируют связывание гуманизированного терапевтического антитела, специфически связывающего онкостатин М человека (hOSM) и модулирующего взаимодействие между hOSM и gp130, содержащего тяжелую цепь с SEQ ID NO: 11 и легкую цепь с SEQ ID NO: 12, с OSM, в частности hOSM, более конкретно с сайтом II hOSM, в твердофазном иммуноферментном анализе (ELISA) при условии, что это конкурирующее антитело не содержит CDRH3 с SEQ ID NO: 42.
2. Фармацевтическая композиция, содержащая конкурирующее антитело по п.1.
3. Способ лечения пациента человека, страдающего заболеванием или расстройством, чувствительным к модуляции взаимодействия между hOSM и gp130 (таким как артритное заболевание, например ревматоидный артрит и/или остеоартрит), включающий стадию введения указанному пациенту терапевтически эффективного количества композиции по п.2.
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GB0407197.3 | 2004-03-30 | ||
| GB0407197A GB0407197D0 (en) | 2004-03-30 | 2004-03-30 | Immunoglobulins |
| GB0407193A GB0407193D0 (en) | 2004-03-30 | 2004-03-30 | Immunoglobulins |
| GB0407193.2 | 2004-03-30 |
Related Parent Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| RU2006134477/10A Division RU2429245C2 (ru) | 2004-03-30 | 2005-03-29 | Иммуноглобулины |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| RU2009108147A true RU2009108147A (ru) | 2010-09-20 |
Family
ID=35064447
Family Applications (5)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| RU2006134477/10A RU2429245C2 (ru) | 2004-03-30 | 2005-03-29 | Иммуноглобулины |
| RU2009108148/10A RU2009108148A (ru) | 2004-03-30 | 2009-03-10 | Иммуноглобулины |
| RU2009108149/10A RU2009108149A (ru) | 2004-03-30 | 2009-03-10 | Иммуноглобулины |
| RU2009108147/10A RU2009108147A (ru) | 2004-03-30 | 2009-03-10 | Иммуноглобулины |
| RU2011121419/10A RU2011121419A (ru) | 2004-03-30 | 2011-05-30 | Иммуноглобулины |
Family Applications Before (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| RU2006134477/10A RU2429245C2 (ru) | 2004-03-30 | 2005-03-29 | Иммуноглобулины |
| RU2009108148/10A RU2009108148A (ru) | 2004-03-30 | 2009-03-10 | Иммуноглобулины |
| RU2009108149/10A RU2009108149A (ru) | 2004-03-30 | 2009-03-10 | Иммуноглобулины |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| RU2011121419/10A RU2011121419A (ru) | 2004-03-30 | 2011-05-30 | Иммуноглобулины |
Country Status (24)
| Country | Link |
|---|---|
| US (2) | US7858753B2 (ru) |
| EP (2) | EP2404935A1 (ru) |
| JP (1) | JP4809828B2 (ru) |
| KR (1) | KR100942849B1 (ru) |
| AR (1) | AR048516A1 (ru) |
| AT (1) | ATE515515T1 (ru) |
| AU (1) | AU2005229457B2 (ru) |
| BR (1) | BRPI0509367A (ru) |
| CA (1) | CA2562953A1 (ru) |
| CY (1) | CY1112192T1 (ru) |
| DK (1) | DK1730191T3 (ru) |
| HR (1) | HRP20110657T1 (ru) |
| IL (1) | IL178119A0 (ru) |
| MA (1) | MA28541B1 (ru) |
| NO (1) | NO20064886L (ru) |
| NZ (1) | NZ550225A (ru) |
| PE (1) | PE20060287A1 (ru) |
| PL (1) | PL1730191T3 (ru) |
| PT (1) | PT1730191E (ru) |
| RU (5) | RU2429245C2 (ru) |
| SG (1) | SG151292A1 (ru) |
| SI (1) | SI1730191T1 (ru) |
| TW (1) | TWI365746B (ru) |
| WO (1) | WO2005095457A2 (ru) |
Families Citing this family (44)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE10303974A1 (de) | 2003-01-31 | 2004-08-05 | Abbott Gmbh & Co. Kg | Amyloid-β(1-42)-Oligomere, Verfahren zu deren Herstellung und deren Verwendung |
| DK1976877T4 (en) | 2005-11-30 | 2017-01-16 | Abbvie Inc | Monoclonal antibodies to amyloid beta protein and uses thereof |
| EP1954718B1 (en) | 2005-11-30 | 2014-09-03 | AbbVie Inc. | Anti-a globulomer antibodies, antigen-binding moieties thereof, corresponding hybridomas, nucleic acids, vectors, host cells, methods of producing said antibodies, compositions comprising said antibodies, uses of said antibodies and methods of using said antibodies |
| WO2007098547A1 (en) * | 2006-03-01 | 2007-09-07 | Apollo Life Sciences Limited | A molecule and chimeric molecules thereof |
| CA2652733C (en) | 2006-05-25 | 2016-06-21 | Glaxo Group Limited | Modified humanised anti-interleukin-18 antibodies |
| US8455626B2 (en) | 2006-11-30 | 2013-06-04 | Abbott Laboratories | Aβ conformer selective anti-aβ globulomer monoclonal antibodies |
| EP2124952A2 (en) | 2007-02-27 | 2009-12-02 | Abbott GmbH & Co. KG | Method for the treatment of amyloidoses |
| PL2305300T3 (pl) | 2008-07-10 | 2016-09-30 | Kompozycja farmaceutyczna do leczenia i zapobiegania nowotworowi | |
| PL2322221T3 (pl) | 2008-08-05 | 2015-01-30 | Toray Industries | Kompozycja farmaceutyczna do leczenia i zapobiegania raka |
| WO2010027797A1 (en) * | 2008-08-26 | 2010-03-11 | Macrogenics Inc. | T-cell receptor antibodies and methods of use thereof |
| US8309688B2 (en) | 2008-12-30 | 2012-11-13 | Centocor Ortho Biotech Inc. | Monkey homolog of human oncostatin M and methods of use thereof |
| EP2258723A1 (en) * | 2009-06-02 | 2010-12-08 | Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. | Treatment of oncostatin M receptor ß mediated heart failure |
| EP2532365B1 (en) | 2010-02-04 | 2016-05-04 | Toray Industries, Inc. | Pharmaceutical composition for treatment and/or prevention of cancer |
| PT2532366T (pt) | 2010-02-04 | 2016-12-20 | Toray Industries | Composição farmacêutica para o tratamento e/ou prevenção de cancro |
| MX340016B (es) | 2010-02-04 | 2016-06-22 | Toray Industries | Composicion farmaceutica para el tratamiento y/o prevencion del cancer. |
| CN102822335B (zh) | 2010-02-04 | 2015-09-30 | 东丽株式会社 | 癌的治疗和/或预防用药物组合物 |
| DK2532680T3 (da) | 2010-02-04 | 2015-07-20 | Toray Industries | Medicinsk sammensætning til behandling og/eller forebyggelse af cancer |
| ES2684475T3 (es) | 2010-04-15 | 2018-10-03 | Abbvie Inc. | Proteínas que se unen a beta amiloide |
| CN105348387B (zh) | 2010-08-14 | 2020-08-25 | Abbvie 公司 | β淀粉样蛋白结合蛋白 |
| WO2012051111A2 (en) | 2010-10-13 | 2012-04-19 | Janssen Biotech, Inc. | Human oncostatin m antibodies and methods of use |
| SMT201800397T1 (it) * | 2010-11-23 | 2018-09-13 | Glaxo Group Ltd | Proteine leganti l'antigene per oncostatina m (osm) |
| PL2740794T3 (pl) | 2011-08-04 | 2018-09-28 | Toray Industries, Inc. | Kompozycja farmaceutyczna do leczenia i/lub profilaktyki nowotworów |
| CN103764825B (zh) | 2011-08-04 | 2015-09-02 | 东丽株式会社 | 癌的治疗和/或预防用药物组合物 |
| US9180188B2 (en) | 2011-08-04 | 2015-11-10 | Toray Industries, Inc. | Pharmaceutical composition for treatment and/or prophylaxis of cancer |
| DK2818482T3 (da) | 2012-02-21 | 2019-07-15 | Toray Industries | Farmaceutisk sammensætning til behandling af cancer |
| ES2643241T3 (es) | 2012-02-21 | 2017-11-21 | Toray Industries, Inc. | Composición medicinal para tratar y/o prevenir el cáncer |
| ES2739380T3 (es) | 2012-02-21 | 2020-01-30 | Toray Industries | Composición farmacéutica para el tratamiento del cáncer |
| MX363136B (es) | 2012-02-21 | 2019-03-12 | Toray Industries | Composicion farmaceutica para el tratamiento y/o prevencion del cancer. |
| JP6107655B2 (ja) | 2012-03-30 | 2017-04-05 | 東レ株式会社 | 胆嚢癌の治療及び／又は予防用医薬組成物 |
| RU2640245C2 (ru) | 2012-03-30 | 2017-12-27 | Торэй Индастриз, Инк. | Фармацевтическая композиция для лечения и/или предотвращения рака печени |
| NZ753995A (en) | 2013-05-30 | 2022-07-01 | Kiniksa Pharmaceuticals Ltd | Oncostatin m receptor antigen binding proteins |
| CA2918989C (en) | 2013-08-09 | 2021-11-02 | Toray Industries, Inc. | Pharmaceutical composition for treatment and/or prevention of cancer |
| US9550828B2 (en) | 2013-09-05 | 2017-01-24 | Boise State University | Oncostatin M (OSM) antagonists for preventing cancer metastasis and IL-6 related disorders |
| AU2014374055B2 (en) | 2013-12-30 | 2018-11-08 | Epimab Biotherapeutics Inc. | Fabs-in-tandem immunoglobulin and uses thereof |
| NZ760008A (en) * | 2014-02-24 | 2023-03-31 | Takeda Pharmaceuticals Co | Uti fusion proteins |
| US20170327573A1 (en) * | 2014-09-24 | 2017-11-16 | Universitá Degli Studi Di Padova | Composition to induce bone marrow stem cell mobilization |
| JP6787904B2 (ja) * | 2015-01-29 | 2020-11-18 | アレス トレーディング ソシエテ アノニム | 高度に正に荷電したタンパク質のイムノアッセイ |
| RU2767329C2 (ru) | 2016-02-06 | 2022-03-17 | Эпимаб Биотерапьютикс, Инк. | Иммуноглобулин с тандемными fab-фрагментами и варианты его применения |
| BR112018069318A2 (pt) | 2016-03-28 | 2019-01-22 | Toray Industries | composição farmacêutica para tratamento e/ou prevenção de um câncer, anticorpo ou fragmento do mesmo, combinação farmacêutica para tratamento e/ou prevenção de um câncer e método para tratar e/ou prevenir um câncer |
| GB201614627D0 (en) * | 2016-08-30 | 2016-10-12 | Glaxosmithkline Ip Dev Ltd | Antigen binding proteins |
| AU2019263850A1 (en) | 2018-05-03 | 2020-11-19 | Shanghai Epimab Biotherapeutics Co., Ltd. | High affinity antibodies to PD-1 and LAG-3 and bispecific binding proteins made therefrom |
| FR3090637A1 (fr) * | 2018-12-21 | 2020-06-26 | Universite De Poitiers | Protéine de liaison spécifique capable de se lier spécifiquement à l’oncostatine M humaine (hOSM) et ses utilisations. |
| US11633457B2 (en) | 2019-04-11 | 2023-04-25 | Boise State University | Pharmaceutical compositions comprising oncostatin m (OSM) antagonist derivatives and methods of use |
| US12180290B2 (en) | 2020-10-19 | 2024-12-31 | Zoetis Services Llc | Antibodies to canine and feline oncostatin M receptor beta and uses thereof |
Family Cites Families (24)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DD266710A3 (de) | 1983-06-06 | 1989-04-12 | Ve Forschungszentrum Biotechnologie | Verfahren zur biotechnischen Herstellung van alkalischer Phosphatase |
| US5807715A (en) | 1984-08-27 | 1998-09-15 | The Board Of Trustees Of The Leland Stanford Junior University | Methods and transformed mammalian lymphocyte cells for producing functional antigen-binding protein including chimeric immunoglobulin |
| US4879231A (en) | 1984-10-30 | 1989-11-07 | Phillips Petroleum Company | Transformation of yeasts of the genus pichia |
| US4676980A (en) | 1985-09-23 | 1987-06-30 | The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services | Target specific cross-linked heteroantibodies |
| GB8610600D0 (en) | 1986-04-30 | 1986-06-04 | Novo Industri As | Transformation of trichoderma |
| DE3883899T3 (de) | 1987-03-18 | 1999-04-22 | Sb2, Inc., Danville, Calif. | Geänderte antikörper. |
| EP0368684B2 (en) | 1988-11-11 | 2004-09-29 | Medical Research Council | Cloning immunoglobulin variable domain sequences. |
| FR2646437B1 (fr) | 1989-04-28 | 1991-08-30 | Transgene Sa | Nouvelles sequences d'adn, leur application en tant que sequence codant pour un peptide signal pour la secretion de proteines matures par des levures recombinantes, cassettes d'expression, levures transformees et procede de preparation de proteines correspondant |
| US6291158B1 (en) | 1989-05-16 | 2001-09-18 | Scripps Research Institute | Method for tapping the immunological repertoire |
| EP0402226A1 (en) | 1989-06-06 | 1990-12-12 | Institut National De La Recherche Agronomique | Transformation vectors for yeast yarrowia |
| DK1266965T3 (da) | 1991-07-25 | 2006-09-25 | Biogen Idec Inc | Rekombinante antistoffer til human terapi |
| ATE181571T1 (de) | 1991-09-23 | 1999-07-15 | Medical Res Council | Methoden zur herstellung humanisierter antikörper |
| GB9122820D0 (en) | 1991-10-28 | 1991-12-11 | Wellcome Found | Stabilised antibodies |
| WO1993008829A1 (en) | 1991-11-04 | 1993-05-13 | The Regents Of The University Of California | Compositions that mediate killing of hiv-infected cells |
| GB9203459D0 (en) | 1992-02-19 | 1992-04-08 | Scotgen Ltd | Antibodies with germ-line variable regions |
| WO1994004690A1 (en) | 1992-08-17 | 1994-03-03 | Genentech, Inc. | Bispecific immunoadhesins |
| DK0703925T3 (da) | 1993-06-03 | 1999-12-06 | Therapeutic Antibodies Inc | Fremstilling af antistoffragmenter |
| JP3622208B2 (ja) | 1993-06-11 | 2005-02-23 | 東ソー株式会社 | 骨粗鬆症治療方法及び治療薬 |
| US5429746A (en) | 1994-02-22 | 1995-07-04 | Smith Kline Beecham Corporation | Antibody purification |
| US5739277A (en) | 1995-04-14 | 1998-04-14 | Genentech Inc. | Altered polypeptides with increased half-life |
| GB9806530D0 (en) * | 1998-03-26 | 1998-05-27 | Glaxo Group Ltd | Inflammatory mediator |
| JP2002512776A (ja) | 1998-04-28 | 2002-05-08 | スミスクライン・ビーチャム・コーポレイション | 免疫原性の低下したモノクローナル抗体 |
| US6881557B2 (en) | 2001-07-12 | 2005-04-19 | Arrowsmith Technologies Llp | Super humanized antibodies |
| GB0216648D0 (en) | 2002-07-18 | 2002-08-28 | Lonza Biologics Plc | Method of expressing recombinant protein in CHO cells |
-
2005
- 2005-03-29 RU RU2006134477/10A patent/RU2429245C2/ru not_active IP Right Cessation
- 2005-03-29 SI SI200531371T patent/SI1730191T1/sl unknown
- 2005-03-29 WO PCT/GB2005/001147 patent/WO2005095457A2/en not_active Ceased
- 2005-03-29 BR BRPI0509367-8A patent/BRPI0509367A/pt not_active IP Right Cessation
- 2005-03-29 US US10/594,293 patent/US7858753B2/en not_active Expired - Fee Related
- 2005-03-29 AU AU2005229457A patent/AU2005229457B2/en not_active Ceased
- 2005-03-29 PL PL05733043T patent/PL1730191T3/pl unknown
- 2005-03-29 PT PT05733043T patent/PT1730191E/pt unknown
- 2005-03-29 EP EP11167424A patent/EP2404935A1/en not_active Withdrawn
- 2005-03-29 JP JP2007505621A patent/JP4809828B2/ja not_active Expired - Fee Related
- 2005-03-29 EP EP05733043A patent/EP1730191B1/en not_active Expired - Lifetime
- 2005-03-29 HR HR20110657T patent/HRP20110657T1/hr unknown
- 2005-03-29 SG SG200901959-7A patent/SG151292A1/en unknown
- 2005-03-29 PE PE2005000360A patent/PE20060287A1/es not_active Application Discontinuation
- 2005-03-29 KR KR1020067022671A patent/KR100942849B1/ko not_active Expired - Fee Related
- 2005-03-29 DK DK05733043.3T patent/DK1730191T3/da active
- 2005-03-29 NZ NZ550225A patent/NZ550225A/en not_active IP Right Cessation
- 2005-03-29 CA CA002562953A patent/CA2562953A1/en not_active Abandoned
- 2005-03-29 AT AT05733043T patent/ATE515515T1/de active
- 2005-03-30 TW TW094110049A patent/TWI365746B/zh not_active IP Right Cessation
- 2005-03-30 AR ARP050101233A patent/AR048516A1/es unknown
-
2006
- 2006-09-14 IL IL178119A patent/IL178119A0/en unknown
- 2006-10-18 MA MA29397A patent/MA28541B1/fr unknown
- 2006-10-26 NO NO20064886A patent/NO20064886L/no not_active Application Discontinuation
-
2009
- 2009-03-10 RU RU2009108148/10A patent/RU2009108148A/ru not_active Application Discontinuation
- 2009-03-10 RU RU2009108149/10A patent/RU2009108149A/ru not_active Application Discontinuation
- 2009-03-10 RU RU2009108147/10A patent/RU2009108147A/ru not_active Application Discontinuation
-
2010
- 2010-11-16 US US12/947,371 patent/US20110245470A1/en not_active Abandoned
-
2011
- 2011-05-30 RU RU2011121419/10A patent/RU2011121419A/ru not_active Application Discontinuation
- 2011-09-29 CY CY20111100943T patent/CY1112192T1/el unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| RU2009108147A (ru) | Иммуноглобулины | |
| RU2421464C2 (ru) | Человеческие антитела к il-13 и их терапевтическое применение | |
| EA200970262A1 (ru) | Композиции и способы, относящиеся к антителам к глюкагоновым рецепторам | |
| MA28982B1 (fr) | Anticorps antagonistes de il-17 | |
| RU2006115835A (ru) | Человеческие антитела против человеческого 4-1вв (cd137) | |
| CY1119353T1 (el) | Θεραπευτικη χρηση αντισωματων anti-cs1 | |
| RU2011144166A (ru) | Способы применения антител к il-22 человека | |
| AR041173A1 (es) | Aniticuerpo monoclonal anti- il- 1r1 humano terapeutico | |
| EE200700052A (et) | Antikeha he v?i mitme apo-lipoproteiin B fragmendi vastu | |
| BRPI0821168B8 (pt) | anticorpo isolado que se liga ao il-21 humano, ou um fragmento deste, usos de dito anticorpo ou fragmento, e, hibridoma | |
| IL200373A (en) | A monoclonal antibody that binds to 3erbb and a pharmacological preparation that includes the same to inhibit 3erbb signaling in humans | |
| DK1684805T3 (da) | Anvendelse af antagonist anti-CD40-monoklonale antistoffer til behandling af multipel myeloma | |
| SE0401601D0 (sv) | Protofibril specific antibodies and uses thereof | |
| EA201190132A1 (ru) | Гуманизированные антитела, связывающиеся с cd19, и их применение | |
| CY1118709T1 (el) | Αντιγονικα πεπτιδια του παραγοντα διεγερσης αποικιων των κοκκινοκυτταρων (gm-csf) και αντισωματα για ton gm-csf | |
| RU2011139083A (ru) | АНТИ-CεmX АНТИТЕЛА, СПОСОБНЫЕ СВЯЗЫВАТЬСЯ С mIgE ЧЕЛОВЕКА В ЛИМФОЦИТАХ | |
| PE20071055A1 (es) | Anticuerpos anti mn | |
| GEP20074222B (en) | Antibodies to cd40 | |
| NZ594466A (en) | Human monoclonal antibodies to protein tyrosine kinase 7 (PTK7) and methods for using anti-PTK7 antibodies | |
| CY1110033T1 (el) | Τεχνητα ανθρωπινα θεραπευτικα αντισωματα εναντια σε ισομορφες cd45 | |
| RU2011140509A (ru) | Гетеродимерные полипептиды il-17a/f и возможности их лечебного применения | |
| EA030259B8 (ru) | Человеческие нейтрализующие антитела к фактору роста нервов (ngf) в качестве селективных ингибиторов метаболического пути ngf | |
| ES2572177T3 (es) | Anticuerpos neutralizantes anti-B7RP1 humanos | |
| RU2011145435A (ru) | БЛОКИРУЮЩИЕ АНТИТЕЛА ПРОТИВ Dkk-1 И ИХ ПРИМЕНЕНИЯ | |
| RU2008152769A (ru) | Гуманизированное антитело против остеопонтина человека |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FA92 | Acknowledgement of application withdrawn (lack of supplementary materials submitted) |
Effective date: 20130703 |